Physician profile
William E Berger
NPI 1538260583
$75,955.61
in general payments reported to CMS, 2019-2025
32 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $13K · 2021: $16K · 2022: $19.54 · 2023: $182 · 2024: $4,913 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $4,811 · Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $4,811.29 |
| Food and Beverage | $570.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15,308.61 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $14,625.72 | 2019-2025 | Fasenra |
| Optinose US, INC. | $10,343.56 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $7,908.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $5,297.69 | 2019 | |
| Hikma Pharmaceuticals USA | $4,685.64 | 2021 | |
| Mylan Specialty L.P. | $3,750.00 | 2020 | |
| Genzyme Corporation | $3,172.60 | 2019-2025 | |
| Mylan INC. | $2,557.00 | 2021 | |
| Alk-Abello, INC | $2,178.66 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Teva Pharmaceuticals USA, INC. | $1,856.02 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,701.86 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $675.00 | 2021 | |
| Abbvie INC. | $575.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $500.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $321.49 | 2019-2021 | |
| Genentech USA, INC. | $204.73 | 2021-2024 | |
| Circassia INC. | $120.59 | 2019-2020 | |
| Horizon Therapeutics Plc | $40.91 | 2019 | |
| Kaleo, INC. | $39.38 | 2019 | |
| Csl Behring | $37.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.95 | 2020 | |
| Glaxosmithkline, LLC. | $17.50 | 2019 | |
| Pharming Healthcare, INC. | $14.93 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.